Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Biogen

Status and phase: Completed; Phase 4

Conditions: Crohn's Disease

Treatments: Drug: natalizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00280956

CD351

Details and patient eligibility

About

The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Male and Female Subjects 18 years and older with Crohn's Disease who have participated in studies CD251, CD301, CD303, CD306, or CD307 per protocol